Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MST-931 Phase 1a in Healthy Adults
NCT07903493Phase 1Recruiting
- Sponsor
- Mabsoft Therapeutics
- Start
- Nov 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MST-931 in ankylosing spondylitis (AS) (5 arms), sponsored by Mabsoft Therapeutics. Primary endpoint: Adverse Events at 113 days. Started Nov 2026; status: recruiting.
02
Drugs
MST-931
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT07903493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07903493.